PDCD1 and neoplasm: Well-known biomarkers, including the expression of PD-L1 on tumor cells and tumor infiltrating lymphocytes (TILs, especially CD8+ tumor infiltrating T cells, and PD-1 positive Teff) (8–11) were not associated with therapeutic efficacy in this study.